T. Rowe Price Associates
OMED

T. Rowe Price Associates’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

T. Rowe Price Associates’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,606
Closed -$190K – 2631
2017
Q1 		$190K Buy
20,606
+19
+0.1% +$167 ﹤0.01% 2404
2016
Q4 		$159K Buy
+20,587
New +$189K ﹤0.01% 2419
2015
Q1 		– Sell
-45,500
Closed -$990K – 2627
2014
Q4 		$990K Sell
45,500
-82,253
-64% -$1.68M ﹤0.01% 1724
2014
Q3 		$2.42M Buy
127,753
+75,717
+146% +$1.52M ﹤0.01% 1551
2014
Q2 		$1.21M Buy
+52,036
New +$1.28M ﹤0.01% 1679
2013
Q4 		– Sell
-69,900
Closed -$1.07M – 2586
2013
Q3 		$1.07M Buy
+69,900
New +$1.3M ﹤0.01% 1652

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's OMED Position: Q2 2017 in Review

T. Rowe Price Associates sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 20,606 shares — an estimated $190K sold.

T. Rowe Price Associates first reported a position in OMED in Q3 2013 and held it in 6 quarters. The position peaked at $2.42M in Q3 2014. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • T. Rowe Price Associates reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 20,606 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $190K.
  • T. Rowe Price Associates first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 6 quarters.
  • T. Rowe Price Associates's OncoMed Pharmaceuticals, Inc. position peaked at $2.42M in Q3 2014.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on T. Rowe Price Associates's 13F filing for Q2 2017, filed 14 Aug 2017.